Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Prospects in blood transfusion].

P Rouger1

  • 1Institut national de la transfusion sanguine, université Paris VI, Inserm U76, 6, rue Alexandre-Cabanel, 75015, Paris, France. prouger@ints.fr <prouger@ints.fr>

Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine
|May 24, 2003
PubMed
Summary

Blood transfusion will remain essential for the next decade, focusing on enhanced safety through advanced testing and improved clinical use of blood products. Blood substitutes are not yet viable alternatives for human use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

International Society of Blood Transfusion Working Party on red cell immunogenetics and blood group terminology: Cancun report (2012).

Vox sanguinis·2013
Same author

Education in transfusion medicine for medical students and doctors.

Vox sanguinis·2013
Same author

[Red-blood-cell allo-immunization].

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2012
Same author

[European Blood Alliance (EBA) and EuroNet TMS: what challenges for the transfusion of tomorrow?].

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2011
Same author

International Society of Blood Transfusion Working Party on red cell immunogenetics and blood group terminology: Berlin report.

Vox sanguinis·2011
Same author

Blood group genotyping by high-throughput DNA analysis: application to the French panel of RBC reagents.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2010

Area of Science:

  • Hematology
  • Transfusion Medicine
  • Biotechnology

Background:

  • The future of blood transfusion services faces challenges from the slow development of viable blood substitutes.
  • Current blood collection methods remain critical for supplying essential blood components.

Purpose of the Study:

  • To outline the expected evolution of blood transfusion over the next 10 years.
  • To provide scientific and medical rationale for decision-makers regarding transfusion advancements.
  • To assess the role of emerging technologies like blood substitutes and cellular therapy.

Main Methods:

  • Review of scientific and clinical studies on blood substitutes and transfusion practices.
  • Analysis of trends in blood product safety, testing, and clinical application.

Related Experiment Videos

  • Projection of future developments in transfusion medicine and cellular therapy.

    • Main Results:

    • Blood substitutes are not yet ready for human clinical application, necessitating continued reliance on human blood collection.
    • Enhancements in blood safety will stem from improved testing techniques and processing of blood products.
    • Optimizing the clinical use of blood derivatives is a key area for development.
    • Cellular therapy is anticipated to be a supplementary service for transfusion centers, in collaboration with hospitals.

    Conclusions:

    • Human blood collection will remain indispensable for producing cell concentrates and fresh frozen plasma in the foreseeable future.
    • The evolution of blood transfusion will prioritize safety through technological advancements and better clinical management of blood products.
    • Cellular therapy represents a potential diversification for transfusion services rather than a replacement for traditional transfusion.